WO1997020580A1 - Drug therapy - Google Patents

Drug therapy Download PDF

Info

Publication number
WO1997020580A1
WO1997020580A1 PCT/GB1996/003000 GB9603000W WO9720580A1 WO 1997020580 A1 WO1997020580 A1 WO 1997020580A1 GB 9603000 W GB9603000 W GB 9603000W WO 9720580 A1 WO9720580 A1 WO 9720580A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
substance
system according
molecule
nh
ring
Prior art date
Application number
PCT/GB1996/003000
Other languages
English (en)
French (fr)
Inventor
Tariq Khan
Original Assignee
Aepact Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
PCT/GB1996/003000 1995-12-06 1996-12-06 Drug therapy WO1997020580A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB9524942.1 1995-12-06
GB9524942A GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP52108297A JP2000502071A (ja) 1995-12-06 1996-12-06 薬物療法
EP19960940685 EP0865298A1 (en) 1995-12-06 1996-12-06 Drug therapy

Publications (1)

Publication Number Publication Date
WO1997020580A1 true true WO1997020580A1 (en) 1997-06-12

Family

ID=10784998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003000 WO1997020580A1 (en) 1995-12-06 1996-12-06 Drug therapy

Country Status (5)

Country Link
EP (1) EP0865298A1 (it)
JP (1) JP2000502071A (it)
CA (1) CA2239203A1 (it)
GB (1) GB9524942D0 (it)
WO (1) WO1997020580A1 (it)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024426A1 (en) * 1998-10-23 2000-05-04 Intelligene Ltd. Ribozymes used as prodrugs
JP2002526457A (ja) * 1998-09-18 2002-08-20 イムノメディクス, インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US6867231B1 (en) 1997-06-14 2005-03-15 Enzacta R & D Limited Therapeutic systems
WO2011036457A1 (en) * 2009-09-23 2011-03-31 Mologic Ltd Peptide clearing agents
WO2014181085A1 (en) 2013-05-09 2014-11-13 Kenneth Dawson Bagshawe Tumour therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
WO1993013805A1 (en) * 1992-01-09 1993-07-22 Kenneth Dawson Bagshawe Cytotoxic drug therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
WO1993013805A1 (en) * 1992-01-09 1993-07-22 Kenneth Dawson Bagshawe Cytotoxic drug therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAGSHAWE K D: "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)", JOURNAL OF CONTROLLED RELEASE, vol. 28, no. 1/03, 1 January 1994 (1994-01-01), pages 187 - 193, XP000435249 *
DOWELL, ROBERT I. ET AL: "New Mustard Prodrugs for Antibody-Directed Enzyme Prodrug Therapy: Alternatives to the Amide Link", J. MED. CHEM. (1996), 39(5), 1100-5 CODEN: JMCMAR;ISSN: 0022-2623, 1996, XP002027294 *
SPRINGER, CAROLINE J. ET AL: "Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy", J. MED. CHEM. (1995), 38(26), 5051-65 CODEN: JMCMAR;ISSN: 0022-2623, 1995, XP002027293 *
SVENSSON H P ET AL: "MONOCLONAL ANTIBODY-B-LACTAMASE CONJUGATES FOR THE ACTIVATION OF A CEPHALOSPORIN MUSTARD PRODRUG", BIOCONJUGATE CHEMISTRY, vol. 3, no. 2, 1 March 1992 (1992-03-01), pages 176 - 181, XP000262174 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867231B1 (en) 1997-06-14 2005-03-15 Enzacta R & D Limited Therapeutic systems
US7138122B2 (en) 1997-06-14 2006-11-21 Enzacta R & D Limited Therapeutic systems
JP2002526457A (ja) * 1998-09-18 2002-08-20 イムノメディクス, インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
WO2000024426A1 (en) * 1998-10-23 2000-05-04 Intelligene Ltd. Ribozymes used as prodrugs
WO2011036457A1 (en) * 2009-09-23 2011-03-31 Mologic Ltd Peptide clearing agents
CN102665768A (zh) * 2009-09-23 2012-09-12 莫洛迪克有限公司 肽清除剂
US8846861B2 (en) 2009-09-23 2014-09-30 Mologic Ltd Peptide clearing agents
CN102665768B (zh) * 2009-09-23 2015-01-21 莫洛迪克有限公司 肽清除剂
WO2014181085A1 (en) 2013-05-09 2014-11-13 Kenneth Dawson Bagshawe Tumour therapy

Also Published As

Publication number Publication date Type
JP2000502071A (ja) 2000-02-22 application
GB9524942D0 (en) 1996-02-07 grant
EP0865298A1 (en) 1998-09-23 application
CA2239203A1 (en) 1997-06-12 application

Similar Documents

Publication Publication Date Title
Han et al. Targeted prodrug design to optimize drug delivery
Ettmayer et al. Lessons learned from marketed and investigational prodrugs
US5349066A (en) Bifunctional linking compounds, conjugates and methods for their production
US7223837B2 (en) Elongated and multiple spacers in activatible prodrugs
US6214345B1 (en) Lysosomal enzyme-cleavable antitumor drug conjugates
US7091186B2 (en) p-Amidobenzylethers in drug delivery agents
US6759509B1 (en) Branched peptide linkers
US20080279868A1 (en) Antibody-Drug Conjugates and Methods of Use
US5112954A (en) Method of enhancing the effect of cytotoxic agents
US4937183A (en) Method for the preparation of antibody-fragment conjugates
US5505931A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0328147A2 (en) Anthracycline immunoconjugates having a novel linker and methods for their production
Niculescu-Duvaz et al. Antibody-directed enzyme prodrug therapy (ADEPT): a review
US5639879A (en) Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging
US7705045B2 (en) Prodrugs built as multiple self-elimination-release spacers
US5686578A (en) Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US7858070B2 (en) Multivalent immunoglobulin-based bioactive assemblies
US7521056B2 (en) Stably tethered structures of defined compositions with multiple functions or binding specificities
US7011812B1 (en) Targeted combination immunotherapy of cancer and infectious diseases
Deonarain et al. Targeting enzymes for cancer therapy: old enzymes in new roles
US20090246211A1 (en) Molecular constructs suitable for targeted conjugates
US20040259768A1 (en) Targeted release
Senter et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate
Farah et al. The development of monoclonal antibodies for the therapy of cancer
US20030138432A1 (en) Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996940685

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2239203

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2239203

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 1997 521082

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996940685

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996940685

Country of ref document: EP